ABVC BioPharma Key Executives
This section highlights ABVC BioPharma's key executives, including their titles and compensation details.
Find Contacts at ABVC BioPharma
(Showing 0 of )
ABVC BioPharma Earnings
This section highlights ABVC BioPharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
$0.98
Stock Price
$15.41M
Market Cap
30
Employees
Fremont, CA
Location
Financial Statements
Access annual & quarterly financial statements for ABVC BioPharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $508.83K | $152.43K | $969.78K | $355.80K | $483.05K |
| Cost of Revenue | $763 | $302.04K | $286.42K | $5.09K | $18.72K |
| Gross Profit | $508.06K | $-149.61K | $683.37K | $350.71K | $464.33K |
| Gross Profit Ratio | 99.85% | -98.15% | 70.47% | 98.57% | 96.13% |
| Research and Development Expenses | $179.27K | $1.06M | $2.69M | $1.00M | $549.66K |
| General and Administrative Expenses | $5.03M | $7.00M | $13.10M | $11.05M | $8.42M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.03M | $7.00M | $13.10M | $11.05M | $8.42M |
| Other Expenses | $- | $- | $83.00K | $-360.90K | $199.64K |
| Operating Expenses | $5.21M | $8.07M | $15.80M | $11.70M | $8.97M |
| Cost and Expenses | $5.21M | $8.37M | $16.08M | $11.70M | $8.99M |
| Interest Income | $87.36K | $185.48K | $187.82K | $43.20K | $71.05K |
| Interest Expense | $825.90K | $2.49M | $293.97K | $227.21K | $405.03K |
| Depreciation and Amortization | $200.92K | $28.53K | $23.80K | $11.99K | $37.14K |
| EBITDA | $-4.34M | $-8.13M | $-15.20M | $-10.97M | $-10.37M |
| EBITDA Ratio | -853.49% | -5335.18% | -1567.03% | -3083.68% | -2147.16% |
| Operating Income | $-4.71M | $-8.22M | $-15.11M | $-11.35M | $-8.51M |
| Operating Income Ratio | -924.73% | -5390.35% | -1558.54% | -3188.64% | -1760.87% |
| Total Other Income Expenses Net | $-664.33K | $-2.44M | $-400.18K | $495.14K | $-2.31M |
| Income Before Tax | $-5.37M | $-10.65M | $-15.51M | $-11.21M | $-10.81M |
| Income Before Tax Ratio | -1055.29% | -6989.62% | -1599.80% | -3150.91% | -2238.70% |
| Income Tax Expense | $-110.54K | $256.01K | $797.78K | $825.02K | $-220.35K |
| Net Income | $-4.90M | $-10.52M | $-16.31M | $-12.04M | $-10.59M |
| Net Income Ratio | -963.57% | -6898.68% | -1682.06% | -3382.79% | -2193.08% |
| EPS | $-0.43 | $-2.43 | $-5.15 | $-4.80 | $-5.37 |
| EPS Diluted | $-0.43 | $-2.43 | $-5.15 | $-4.80 | $-5.37 |
| Weighted Average Shares Outstanding | 12.41M | 4.34M | 3.17M | 2.51M | 1.97M |
| Weighted Average Shares Outstanding Diluted | 12.41M | 4.34M | 3.17M | 2.51M | 1.97M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.97K | $389.28K | $117.14K | $1.21K | $2.17K | $15.88K | $6.11K | $128.27K | $588.99K | $42.27K | $312.86K | $25.66K | $-37.79K | $99.00K | $31.44K | $263.15K | $62.19K | $115.55K | $226.51K | $78.79K |
| Cost of Revenue | $- | $296 | $190 | $1.56K | $146.79K | $29.61K | $72.98K | $60.24K | $265.41K | $10.74K | $8.37K | $1.90K | $2.80K | $393 | $646 | $1.25K | $1.90K | $8.62K | $4.24K | $3.96K |
| Gross Profit | $1.97K | $388.98K | $116.95K | $-358 | $-144.62K | $-13.73K | $-66.87K | $68.04K | $323.58K | $31.53K | $304.49K | $23.76K | $-40.59K | $98.61K | $30.80K | $261.90K | $60.29K | $106.93K | $222.28K | $74.83K |
| Gross Profit Ratio | 100.00% | 99.92% | 99.84% | -29.71% | -6680.05% | -86.44% | -1094.65% | 53.04% | 54.94% | 74.59% | 97.33% | 92.61% | 107.41% | 99.60% | 97.95% | 99.53% | 96.94% | 92.54% | 98.13% | 94.97% |
| Research and Development Expenses | $31.98K | $37.83K | $40.40K | $69.07K | $72.19K | $141.31K | $514.44K | $334.98K | $1.50M | $305.48K | $532.78K | $359.40K | $260.19K | $263.42K | $358.88K | $121.31K | $183.28K | $134.50K | $139.08K | $92.79K |
| General and Administrative Expenses | $304.14K | $- | $1.05M | $3.38M | $1.75M | $2.00M | $1.61M | $1.64M | $1.96M | $3.44M | $1.82M | $5.88M | $6.15M | $1.81M | $1.71M | $1.39M | $2.43M | $- | $1.28M | $1.15M |
| Selling and Marketing Expenses | $- | $- | $- | $-1.29K | $-7.58K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.30M | $- | $- | $- |
| Selling General and Administrative Expenses | $304.14K | $301.21K | $1.05M | $3.37M | $1.74M | $2.00M | $1.61M | $1.64M | $1.96M | $3.44M | $1.82M | $5.88M | $6.15M | $1.81M | $1.71M | $1.39M | $4.73M | $1.26M | $1.28M | $1.15M |
| Other Expenses | $- | $- | $- | $30.48K | $16.56K | $-10.77K | $38.33K | $25.17K | $63.86K | $22.09K | $-17.66K | $14.71K | $97.53K | $3.42K | $54.29K | $6.54K | $4.46K | $5.80K | $176.63K | $12.75K |
| Operating Expenses | $336.12K | $339.03K | $1.09M | $3.44M | $1.82M | $2.14M | $2.13M | $1.97M | $3.46M | $3.75M | $2.35M | $6.24M | $6.30M | $1.94M | $2.07M | $1.39M | $4.91M | $1.40M | $1.42M | $1.25M |
| Cost and Expenses | $336.12K | $339.33K | $1.09M | $3.45M | $1.96M | $2.17M | $2.20M | $2.03M | $3.72M | $3.76M | $2.36M | $6.24M | $6.31M | $1.94M | $2.07M | $1.39M | $4.91M | $1.41M | $1.42M | $1.25M |
| Interest Income | $11.91K | $44.26K | $27.14K | $4.05K | $37.48K | $40.25K | $55.04K | $52.71K | $60.46K | $48.16K | $39.02K | $40.17K | $- | $9.33K | $10.72K | $52.53K | $31.40K | $19.57K | $9.35K | $10.72K |
| Interest Expense | $-338.35K | $219.53K | $260.03K | $684.68K | $1.10M | $1.22M | $114.75K | $56.66K | $134.46K | $126.54K | $14.76K | $18.21K | $- | $38.68K | $82.67K | $130.23K | $116.68K | $16.31K | $140.53K | $131.52K |
| Depreciation and Amortization | $179.32K | $7.01K | $13.30K | $1.29K | $7.58K | $7.46K | $7.00K | $6.49K | $6.43K | $6.46K | $26.85K | $60.30K | $3.27K | $2.86K | $2.94K | $2.93K | $6.81K | $8.73K | $10.43K | $11.17K |
| EBITDA | $-30.09K | $92.63K | $-1.11M | $-3.30M | $-2.04M | $-2.14M | $-2.11M | $-1.83M | $-3.40M | $-3.64M | $-2.01M | $-6.15M | $-6.27M | $-1.92M | $-2.03M | $-1.11M | $-4.93M | $-2.15M | $-2.08M | $-1.21M |
| EBITDA Ratio | -1530.52% | 23.79% | -947.77% | -273448.55% | -94390.90% | -13491.55% | -34568.41% | -1429.83% | -576.77% | -8609.87% | -642.31% | -23970.60% | 16594.54% | -1939.80% | -6446.89% | -423.02% | -7930.22% | -1861.33% | -919.04% | -1532.18% |
| Operating Income | $-334.16K | $49.95K | $-976.64K | $-3.44M | $-1.96M | $-2.15M | $-2.19M | $-1.91M | $-3.13M | $-3.72M | $-2.05M | $-6.22M | $-6.45M | $-1.97M | $-2.04M | $-1.25M | $-4.85M | $-1.29M | $-1.19M | $-1.17M |
| Operating Income Ratio | -16996.85% | 12.83% | -833.72% | -285841.49% | -90605.54% | -13566.31% | -35911.64% | -1486.05% | -531.92% | -8790.94% | -654.24% | -24235.08% | 17059.12% | -1990.48% | -6474.28% | -476.06% | -7799.30% | -1116.17% | -527.13% | -1486.78% |
| Total Other Income Expenses Net | $463.10K | $-183.86K | $-406.94K | $-536.63K | $-1.19M | $-1.21M | $-39.69K | $8.95K | $-405.04K | $-56.46K | $17.08K | $44.24K | $557.11K | $8.64K | $-77.00K | $6.40K | $-204.92K | $-886.10K | $-1.04M | $-178.45K |
| Income Before Tax | $128.94K | $-133.92K | $-1.38M | $-3.98M | $-3.15M | $-3.37M | $-2.23M | $-1.90M | $-3.54M | $-3.77M | $-2.03M | $-6.17M | $-5.89M | $-1.96M | $-2.11M | $-1.25M | $-5.06M | $-2.18M | $-2.23M | $-1.35M |
| Income Before Tax Ratio | 6558.65% | -34.40% | -1181.12% | -330375.02% | -145701.76% | -21210.52% | -36561.30% | -1479.07% | -600.69% | -8924.51% | -648.78% | -24062.67% | 15585.03% | -1981.75% | -6719.21% | -473.63% | -8128.79% | -1883.00% | -985.68% | -1713.29% |
| Income Tax Expense | $- | $355 | $-110.89K | $-3.93M | $175.31K | $-999 | $81.69K | $-1.82M | $962.87K | $4.22K | $-82.45K | $-86.87K | $1.01M | $-75.67K | $-59.56K | $-51.02K | $-86.41K | $-44.73K | $-48.64K | $-40.57K |
| Net Income | $229.30K | $-186.56K | $-1.01M | $-3.93M | $-3.11M | $-3.32M | $-2.26M | $-73.53K | $-4.50M | $-3.78M | $-1.95M | $-6.09M | $-7.93M | $-1.81M | $-1.97M | $-1.13M | $-4.85M | $-1.85M | $-1.85M | $-1.25M |
| Net Income Ratio | 11663.48% | -47.93% | -864.46% | -326388.05% | -143692.10% | -20885.90% | -37052.07% | -57.33% | -764.17% | -8934.50% | -622.43% | -23724.14% | 20988.69% | -1824.75% | -6270.88% | -428.84% | -7795.54% | -1597.58% | -816.42% | -1583.45% |
| EPS | $0.02 | $-0.02 | $-0.09 | $-0.40 | $-0.39 | $-0.82 | $-0.68 | $-0.02 | $-1.38 | $-1.16 | $-0.62 | $-2.05 | $-3.16 | $-0.70 | $-0.81 | $-0.46 | $-2.44 | $-0.95 | $-0.95 | $-0.64 |
| EPS Diluted | $0.02 | $-0.02 | $-0.09 | $-0.40 | $-0.39 | $-0.82 | $-0.68 | $-0.02 | $-1.38 | $-1.16 | $-0.62 | $-2.05 | $-3.16 | $-0.67 | $-0.81 | $-0.46 | $-2.38 | $-0.95 | $-0.95 | $-0.64 |
| Weighted Average Shares Outstanding | 12.41M | 12.41M | 11.32M | 9.74M | 7.94M | 4.06M | 3.31M | 3.31M | 3.26M | 3.26M | 3.13M | 2.97M | 2.51M | 2.58M | 2.44M | 2.44M | 1.98M | 1.95M | 1.95M | 1.95M |
| Weighted Average Shares Outstanding Diluted | 12.41M | 12.41M | 11.32M | 9.74M | 7.94M | 4.06M | 3.31M | 3.31M | 3.26M | 3.26M | 3.13M | 2.97M | 2.51M | 2.69M | 2.44M | 2.44M | 2.04M | 1.95M | 1.95M | 1.95M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $248.38K | $60.16K | $85.27K | $5.83M | $4.27M |
| Short Term Investments | $64.74K | $79.31K | $75.80K | $108.15K | $- |
| Cash and Short Term Investments | $313.12K | $139.47K | $161.06K | $5.94M | $4.27M |
| Net Receivables | $1.16M | $759.57K | $1.37M | $1.71M | $999.40K |
| Inventory | $- | $- | $1.31M | $25.98K | $-839.69K |
| Other Current Assets | $1.87M | $757.68K | $1.46M | $1.95M | $900.36K |
| Total Current Assets | $2.18M | $1.66M | $2.99M | $9.63M | $6.17M |
| Property Plant Equipment Net | $1.15M | $8.78M | $1.74M | $2.00M | $2.29M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $2.26M | $2.53M | $3.68M | $932.75K | $1.19M |
| Tax Assets | $- | $- | $117.11K | $981.91K | $1.79M |
| Other Non-Current Assets | $1.95M | $1.53M | $1.34M | $160.47K | $164.83K |
| Total Non-Current Assets | $5.36M | $12.84M | $6.87M | $4.07M | $5.43M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $7.54M | $14.49M | $9.86M | $13.70M | $11.61M |
| Account Payables | $- | $- | $- | $- | $23.04K |
| Short Term Debt | $2.19M | $1.87M | $2.26M | $1.99M | $2.40M |
| Tax Payables | $- | $112.95K | $- | $- | $- |
| Deferred Revenue | $81.11K | $79.50K | $10.98K | $10.98K | $12.07K |
| Other Current Liabilities | $4.28M | $3.87M | $3.27M | $1.69M | $2.41M |
| Total Current Liabilities | $6.56M | $5.93M | $5.82M | $3.69M | $4.84M |
| Long Term Debt | $236.81K | $407.46K | $791.83K | $1.12M | $4.08M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $21.68K | $21.68K | $7.98K | $10.58K | $19.28K |
| Total Non-Current Liabilities | $258.49K | $429.14K | $420.23K | $1.14M | $4.10M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $6.82M | $6.36M | $6.24M | $4.83M | $8.94M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $13.87K | $7.94K | $32.86K | $28.93K | $24.42K |
| Retained Earnings | $-68.95M | $-65.42M | $-54.90M | $-38.48M | $-25.64M |
| Accumulated Other Comprehensive Income Loss | $445.67K | $516.39K | $517.13K | $539.66K | $564.86K |
| Other Total Stockholders Equity | $69.72M | $73.28M | $57.48M | $46.76M | $28.49M |
| Total Stockholders Equity | $1.23M | $8.39M | $3.10M | $8.84M | $3.44M |
| Total Equity | $723.96K | $8.13M | $3.62M | $8.87M | $2.66M |
| Total Liabilities and Stockholders Equity | $7.54M | $14.49M | $9.86M | $13.70M | $11.61M |
| Minority Interest | $-502.18K | $-257.08K | $517.13K | $26.69K | $-776.27K |
| Total Liabilities and Total Equity | $7.54M | $14.49M | $9.86M | $13.70M | $11.61M |
| Total Investments | $2.32M | $2.61M | $917.87K | $1.04M | $1.19M |
| Total Debt | $2.43M | $2.28M | $3.05M | $3.11M | $6.48M |
| Net Debt | $2.18M | $2.22M | $2.97M | $-2.72M | $2.21M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $248.38K | $137.34K | $124.30K | $659.00K | $716.78K | $500.07K | $99.29K | $1.13M | $85.27K | $1.32M | $2.91M | $2.72M | $5.83M | $3.72M | $924.84K | $2.62M | $4.27M | $135.71K | $390.22K | $123.64K |
| Short Term Investments | $64.74K | $70.81K | $75.68K | $75.92K | $79.31K | $68.52K | $76.79K | $78.01K | $75.80K | $77.58K | $82.75K | $95.55K | $108.15K | $111.32K | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $313.12K | $208.15K | $199.98K | $734.92K | $796.09K | $568.59K | $176.08K | $1.21M | $161.06K | $1.40M | $2.99M | $2.81M | $5.94M | $3.83M | $924.84K | $2.62M | $4.27M | $135.71K | $390.22K | $123.64K |
| Net Receivables | $1.16M | $1.22M | $1.27M | $899.93K | $759.57K | $1.16M | $1.16M | $1.26M | $1.37M | $547.68K | $4.15M | $3.14M | $1.71M | $1.03M | $1.15M | $1.24M | $999.40K | $925.31K | $1.12M | $591.67K |
| Inventory | $- | $- | $- | $- | $- | $620.87K | $-583.35K | $-1.22M | $1.31M | $20.49K | $21.86K | $22.70K | $25.98K | $60.01K | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $711.65K | $723.82K | $719.28K | $159.60K | $757.68K | $764.00K | $790.92K | $1.00M | $1.46M | $933.78K | $2.63M | $2.01M | $1.27M | $2.19M | $1.55M | $1.35M | $900.36K | $116.77K | $98.52K | $87.17K |
| Total Current Assets | $2.18M | $2.15M | $2.19M | $1.79M | $1.66M | $2.49M | $2.13M | $3.48M | $2.99M | $2.90M | $9.79M | $7.99M | $9.63M | $7.11M | $3.63M | $5.21M | $6.17M | $1.18M | $1.60M | $802.49K |
| Property Plant Equipment Net | $1.15M | $8.44M | $8.54M | $8.66M | $8.78M | $8.85M | $1.56M | $1.67M | $1.74M | $1.81M | $1.89M | $1.98M | $2.00M | $2.08M | $2.15M | $2.22M | $2.29M | $2.35M | $890.90K | $955.09K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $2.26M | $2.33M | $2.38M | $2.82M | $3.09M | $2.68M | $831.71K | $849.84K | $842.07K | $816.16K | $870.57K | $904.25K | $932.75K | $1.01M | $1.10M | $1.13M | $1.19M | $1.19M | $2.20M | $3.26M |
| Tax Assets | $- | $- | $- | $- | $- | $34.26K | $35.47K | $118.19K | $117.11K | $1.01M | $1.08M | $1.04M | $981.91K | $1.99M | $1.91M | $1.82M | $1.79M | $1.65M | $1.58M | $1.49M |
| Other Non-Current Assets | $1.95M | $1.54M | $1.53M | $1.41M | $1.42M | $2.53M | $4.76M | $4.62M | $4.17M | $3.94M | $150.08K | $156.40K | $160.47K | $161.42K | $161.03K | $158.28K | $164.83K | $161.80K | $159.75K | $156.06K |
| Total Non-Current Assets | $5.36M | $12.31M | $12.44M | $12.89M | $13.29M | $14.10M | $7.19M | $7.25M | $6.87M | $7.58M | $3.99M | $4.08M | $4.07M | $5.24M | $5.32M | $5.32M | $5.43M | $5.35M | $4.83M | $5.86M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-300 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $7.54M | $14.46M | $14.63M | $14.69M | $14.94M | $16.59M | $9.32M | $10.73M | $9.86M | $10.48M | $13.78M | $12.07M | $13.70M | $12.35M | $8.94M | $10.53M | $11.61M | $6.53M | $6.43M | $6.67M |
| Account Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.08K | $- | $- | $16.50K | $5.05K | $10.33K | $23.04K | $23.07K | $7.81K | $20.36K |
| Short Term Debt | $2.19M | $2.18M | $2.18M | $2.09M | $1.87M | $1.25M | $1.27M | $1.29M | $2.26M | $2.23M | $1.92M | $2.14M | $1.99M | $2.17M | $2.18M | $2.15M | $2.40M | $2.74M | $4.16M | $4.40M |
| Tax Payables | $- | $- | $- | $108.11K | $112.95K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $81.11K | $79.50K | $79.50K | $79.50K | $79.50K | $79.50K | $79.50K | $10.98K | $10.98K | $10.98K | $10.98K | $10.98K | $10.98K | $10.98K | $10.98K | $12.07K | $12.07K | $13.42K | $13.92K | $13.09K |
| Other Current Liabilities | $4.28M | $4.05M | $4.29M | $4.35M | $3.87M | $4.04M | $4.42M | $3.77M | $3.55M | $1.65M | $2.17M | $1.51M | $1.69M | $1.25M | $2.50M | $2.85M | $2.41M | $3.81M | $3.87M | $3.93M |
| Total Current Liabilities | $6.56M | $6.32M | $6.55M | $6.63M | $5.93M | $5.36M | $5.77M | $5.07M | $5.82M | $3.89M | $3.65M | $3.66M | $3.69M | $3.44M | $4.38M | $4.67M | $4.84M | $6.05M | $7.57M | $7.65M |
| Long Term Debt | $236.81K | $142.20K | $228.80K | $318.15K | $407.46K | $2.16M | $3.91M | $3.92M | $791.83K | $880.18K | $944.27K | $1.03M | $1.12M | $1.32M | $4.04M | $4.12M | $4.08M | $1.66M | $297.39K | $179.99K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $21.68K | $25.68K | $27.68K | $21.68K | $21.68K | $5.68K | $5.68K | $7.48K | $7.98K | $12.88K | $11.98K | $7.98K | $10.58K | $9.88K | $17.18K | $11.08K | $19.28K | $20.03K | $4.68K | $2.88K |
| Total Non-Current Liabilities | $258.49K | $167.88K | $256.48K | $339.83K | $429.14K | $2.17M | $3.91M | $3.93M | $799.81K | $893.06K | $956.25K | $1.04M | $1.14M | $1.33M | $4.05M | $4.13M | $4.10M | $1.68M | $302.07K | $182.87K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $6.82M | $6.48M | $6.81M | $6.97M | $6.36M | $7.53M | $9.69M | $9.00M | $6.62M | $4.79M | $4.60M | $4.71M | $4.83M | $4.77M | $8.43M | $8.80M | $8.94M | $7.72M | $7.88M | $7.84M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $13.87K | $12.71K | $12.05K | $10.70K | $7.94K | $4.82K | $3.31K | $33.08K | $32.86K | $32.63K | $32.31K | $30.31K | $28.93K | $27.93K | $24.47K | $24.42K | $24.42K | $20.39K | $19.49K | $19.49K |
| Retained Earnings | $-68.95M | $-70.55M | $-70.37M | $-69.35M | $-65.42M | $-62.31M | $-58.99M | $-56.73M | $-54.90M | $-50.04M | $-46.34M | $-44.48M | $-38.48M | $-30.55M | $-28.74M | $-26.77M | $-25.64M | $-20.79M | $-18.95M | $-17.10M |
| Accumulated Other Comprehensive Income Loss | $445.67K | $461.28K | $466.93K | $233.32K | $516.39K | $519.12K | $534.21K | $546.24K | $517.13K | $113.08K | $303.10K | $426.32K | $539.66K | $981.72K | $965.58K | $601.00K | $564.86K | $621.35K | $646.73K | $657.30K |
| Other Total Stockholders Equity | $69.72M | $78.44M | $78.18M | $77.13M | $73.28M | $70.89M | $58.07M | $57.82M | $57.45M | $55.81M | $55.33M | $51.45M | $49.01M | $38.13M | $29.19M | $28.72M | $28.49M | $19.62M | $17.21M | $15.29M |
| Total Stockholders Equity | $1.23M | $8.36M | $8.29M | $8.02M | $8.84M | $9.10M | $-379.31K | $1.67M | $3.10M | $5.92M | $9.33M | $7.43M | $8.84M | $8.59M | $1.44M | $2.57M | $3.44M | $-536.42K | $-1.07M | $-1.14M |
| Total Equity | $723.96K | $7.98M | $7.83M | $7.71M | $8.58M | $9.06M | $-367.01K | $1.73M | $3.24M | $5.69M | $9.18M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $7.54M | $14.46M | $14.63M | $14.69M | $14.94M | $16.59M | $9.32M | $10.73M | $9.86M | $10.48M | $13.78M | $12.07M | $13.70M | $12.35M | $8.94M | $10.53M | $11.61M | $6.53M | $6.43M | $6.67M |
| Minority Interest | $-502.18K | $-379.14K | $-465.17K | $-305.12K | $-257.08K | $-38.26K | $12.30K | $64.02K | $137.55K | $-225.48K | $-153.82K | $-65.49K | $26.69K | $-1.00M | $-924.48K | $-843.09K | $-776.27K | $-655.42K | $-370.34K | $-35.58K |
| Total Liabilities and Total Equity | $7.54M | $14.46M | $14.63M | $14.69M | $14.94M | $16.59M | $9.32M | $10.73M | $9.86M | $10.48M | $13.78M | $12.07M | $13.70M | $12.35M | $8.94M | $10.53M | $11.61M | $6.53M | $6.43M | $6.67M |
| Total Investments | $2.32M | $2.40M | $2.45M | $2.90M | $3.17M | $2.75M | $831.71K | $849.84K | $917.87K | $893.74K | $953.33K | $999.81K | $1.04M | $1.12M | $1.10M | $1.13M | $1.19M | $1.19M | $2.20M | $3.26M |
| Total Debt | $2.43M | $2.33M | $2.41M | $2.71M | $2.45M | $3.41M | $5.18M | $5.21M | $3.05M | $3.11M | $2.87M | $3.17M | $3.30M | $3.48M | $6.21M | $6.27M | $6.48M | $4.39M | $4.46M | $4.58M |
| Net Debt | $2.18M | $2.19M | $2.29M | $2.05M | $1.73M | $2.91M | $5.08M | $4.07M | $2.97M | $1.79M | $-42.06K | $455.89K | $-2.53M | $-233.87K | $5.29M | $3.66M | $2.21M | $4.26M | $4.07M | $4.46M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-5.26M | $-10.52M | $-16.31M | $-12.04M | $-10.59M |
| Depreciation and Amortization | $200.92K | $28.53K | $23.80K | $11.99K | $37.14K |
| Deferred Income Tax | $- | $115.67K | $864.80K | $824.20K | $-223.20K |
| Stock Based Compensation | $- | $1.64M | $7.04M | $5.31M | $4.15M |
| Change in Working Capital | $-408.42K | $976.96K | $635.57K | $-1.61M | $-86.43K |
| Accounts Receivables | $- | $228.56K | $-614.17K | $-120.98K | $3.70K |
| Inventory | $- | $- | $25.98K | $-25.83K | $-88.16K |
| Accounts Payables | $- | $- | $- | $-23.04K | $-951 |
| Other Working Capital | $-408.42K | $748.40K | $1.22M | $-1.44M | $-1.01K |
| Other Non Cash Items | $3.66M | $3.52M | $353.04K | $-91.05K | $2.16M |
| Net Cash Provided by Operating Activities | $-1.81M | $-4.24M | $-7.40M | $-7.60M | $-4.56M |
| Investments in Property Plant and Equipment | $- | $-21.20K | $-119.69K | $-17.50K | $- |
| Acquisitions Net | $- | $-338.99K | $-1.60M | $-680.92K | $- |
| Purchases of Investments | $- | $- | $-1.60M | $-107.55K | $- |
| Sales Maturities of Investments | $- | $- | $3.20M | $788.46K | $147.80K |
| Other Investing Activities | $- | $- | $-1.60M | $-788.46K | $-373.24K |
| Net Cash Used for Investing Activities | $- | $-360.19K | $-1.72M | $-805.97K | $-225.43K |
| Debt Repayment | $15.93K | $462.62K | $350.00K | $-177.74K | $1.95M |
| Common Stock Issued | $31.04K | $1.05M | $3.66M | $11.12M | $7.62M |
| Common Stock Repurchased | $-7.32K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.94M | $2.41M | $- | $-946.16K | $- |
| Net Cash Used Provided by Financing Activities | $1.98M | $3.92M | $4.01M | $10.00M | $9.57M |
| Effect of Forex Changes on Cash | $-24.59K | $2.12K | $-67.34K | $-28.02K | $62.44K |
| Net Change in Cash | $147.03K | $-674.95K | $-5.17M | $1.56M | $4.84M |
| Cash at End of Period | $863.82K | $716.78K | $1.39M | $6.57M | $5.00M |
| Cash at Beginning of Period | $716.78K | $1.39M | $6.57M | $5.00M | $160.44K |
| Operating Cash Flow | $-1.81M | $-4.24M | $-7.40M | $-7.60M | $-4.56M |
| Capital Expenditure | $- | $-21.20K | $-119.69K | $-17.50K | $- |
| Free Cash Flow | $-1.81M | $-4.26M | $-7.52M | $-7.62M | $-4.56M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $128.94K | $-186.56K | $-1.01M | $-3.93M | $-3.11M | $-3.37M | $-2.32M | $-1.90M | $-4.50M | $-3.78M | $-1.95M | $-6.09M | $-6.90M | $-1.89M | $-2.05M | $-1.20M | $-4.97M | $-2.13M | $-2.18M | $-1.31M |
| Depreciation and Amortization | $179.32K | $7.01K | $13.30K | $1.29K | $7.58K | $7.46K | $7.00K | $6.49K | $6.43K | $6.46K | $5.49K | $5.41K | $3.27K | $2.86K | $2.94K | $2.93K | $6.81K | $8.73K | $10.43K | $11.17K |
| Deferred Income Tax | $- | $- | $- | $- | $151.39K | $-117.41K | $81.69K | $- | $896.05K | $138.87K | $-83.25K | $-86.87K | $1.01M | $-75.67K | $-60.36K | $-51.02K | $-86.40K | $-44.73K | $-51.49K | $-40.57K |
| Stock Based Compensation | $-184.28K | $- | $412.74K | $2.54M | $225.74K | $817.74K | $225.74K | $366.49K | $1.89M | $225.74K | $225.74K | $4.69M | $4.38M | $225.74K | $475.74K | $225.74K | $3.15M | $999.22K | $75 | $525 |
| Change in Working Capital | $-220.56K | $12.61K | $-514.37K | $160.72K | $-146.82K | $1.79K | $938.16K | $28.14K | $1.44M | $2.36M | $-1.64M | $-1.53M | $-521.44K | $-910.58K | $137.04K | $-318.79K | $-398.74K | $-46.48K | $-280.32K | $639.11K |
| Accounts Receivables | $173.46K | $140.36K | $- | $-140.36K | $-474.24K | $9.70K | $68.23K | $113.34K | $-582.26K | $-23.13K | $-8.28K | $-505 | $50.67K | $-34.34K | $101.17K | $-238.48K | $-10.36K | $53.90K | $-92.80K | $52.95K |
| Inventory | $- | $- | $- | $- | $68.52K | $- | $- | $- | $-5.49K | $3.01K | $-64 | $2.54K | $33.84K | $- | $- | $- | $-387.01K | $-115.14K | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $112.95K | $- | $- | $- | $- | $-2.08K | $2.08K | $- | $-16.50K | $11.45K | $-5.29K | $-12.71K | $-30 | $15.26K | $-12.55K | $-3.63K |
| Other Working Capital | $-394.02K | $-127.75K | $-514.37K | $301.08K | $145.95K | $-7.91K | $869.93K | $-113.34K | $2.03M | $2.38M | $-1.63M | $-1.53M | $-589.46K | $-887.69K | $41.16K | $-67.59K | $-1.35K | $-504 | $-174.97K | $589.79K |
| Other Non Cash Items | $-397.04K | $338.66K | $86.87K | $3.31M | $2.41M | $1.30M | $162.81K | $-1.52K | $-199.48K | $533.69K | $9.33K | $9.50K | $-27.47K | $-40.57K | $53.59K | $-76.61K | $112.26K | $885.60K | $1.09M | $68.08K |
| Net Cash Provided by Operating Activities | $-493.61K | $171.72K | $-1.01M | $-602.00K | $-462.00K | $-1.36M | $-899.83K | $-1.50M | $-461.07K | $-513.70K | $-3.43M | $-2.99M | $-2.06M | $-2.68M | $-1.44M | $-1.41M | $-2.19M | $-328.80K | $-1.42M | $-630.94K |
| Investments in Property Plant and Equipment | $- | $-3 | $3 | $- | $21.20K | $-21.20K | $- | $- | $-89 | $-4.36K | $-22.03K | $-93.22K | $281.95K | $- | $- | $-281.95K | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $-83.20K | $-1.52M | $- | $- | $-44.74K | $-214.20K | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $154.17K | $-52.58K | $-440.57K | $- | $-83.20K | $-1.52M | $93.22K | $- | $3.15K | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $166.40K | $3.04M | $- | $- | $-550.18K | $- | $- | $- | $10.72K | $103.79K | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $-21.20K | $-52.58K | $-440.57K | $- | $-83.20K | $-1.52M | $-93.22K | $- | $268.23K | $-128.20K | $-140.02K | $- | $96.39K | $-469.63K | $33.30K | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $154.17K | $-73.78K | $-440.57K | $- | $-83.29K | $-1.52M | $-22.03K | $-93.22K | $-41.59K | $-342.40K | $-140.02K | $-281.95K | $107.11K | $-365.84K | $33.30K | $- |
| Debt Repayment | $-87.04K | $-179.12K | $24.33K | $410.94K | $110.11K | $-1.82M | $-31.59K | $3.21M | $- | $350.00K | $- | $- | $8.36K | $-107.10K | $-61.23K | $1.78K | $1.41M | $480.99K | $-253.38K | $342.65K |
| Common Stock Issued | $-133.73K | $33.73K | $737.50K | $394.07K | $-22.69K | $1.05M | $- | $- | $-253.50K | $253.50K | $3.66M | $- | $4.24M | $6.88M | $-40.45K | $40.45K | $5.46M | $456.18K | $1.43M | $267.74K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $809.55K | $- | $844.21K | $265.23K | $-22.69K | $2.43M | $- | $-1.00M | $- | $- | $- | $- | $- | $-950.43K | $-15.28K | $- | $- | $-493.48K | $468.79K | $- |
| Net Cash Used Provided by Financing Activities | $581.46K | $-145.39K | $868.54K | $805.01K | $87.42K | $1.66M | $-31.59K | $2.21M | $-253.50K | $603.50K | $3.66M | $- | $4.25M | $5.82M | $-116.96K | $42.23K | $6.87M | $443.69K | $1.64M | $610.39K |
| Effect of Forex Changes on Cash | $6.10K | $773 | $229.32K | $-260.78K | $-166.29K | $154.92K | $322.30K | $-308.80K | $219.44K | $-195.75K | $-45.88K | $-45.15K | $-39.60K | $2.16K | $24.75K | $-15.34K | $61.41K | $-3.56K | $4.68K | $-93 |
| Net Change in Cash | $93.94K | $27.10K | $83.77K | $-57.78K | $-404.16K | $378.75K | $-1.05M | $400.15K | $-578.42K | $-1.63M | $166.66K | $-3.13M | $2.12M | $2.79M | $-1.68M | $-1.67M | $4.85M | $-254.52K | $266.58K | $-20.65K |
| Cash at End of Period | $863.82K | $769.87K | $742.77K | $659.00K | $716.78K | $1.12M | $742.19K | $1.79M | $1.39M | $1.97M | $3.60M | $3.43M | $6.57M | $4.45M | $1.66M | $3.33M | $5.00M | $151.85K | $406.37K | $139.79K |
| Cash at Beginning of Period | $769.87K | $742.77K | $659.00K | $716.78K | $1.12M | $742.19K | $1.79M | $1.39M | $1.97M | $3.60M | $3.43M | $6.57M | $4.45M | $1.66M | $3.33M | $5.00M | $151.85K | $406.37K | $139.79K | $160.44K |
| Operating Cash Flow | $-493.61K | $171.72K | $-1.01M | $-602.00K | $-462.00K | $-1.36M | $-899.83K | $-1.50M | $-461.07K | $-513.70K | $-3.43M | $-2.99M | $-2.06M | $-2.68M | $-1.44M | $-1.41M | $-2.19M | $-328.80K | $-1.42M | $-630.94K |
| Capital Expenditure | $- | $-3 | $3 | $- | $21.20K | $-21.20K | $- | $- | $-89 | $-4.36K | $-22.03K | $-93.22K | $281.95K | $- | $- | $-281.95K | $- | $- | $- | $- |
| Free Cash Flow | $-493.61K | $171.72K | $-1.01M | $-602.00K | $-440.80K | $-1.38M | $-899.83K | $-1.50M | $-461.16K | $-518.06K | $-3.45M | $-3.09M | $-1.77M | $-2.68M | $-1.44M | $-1.70M | $-2.19M | $-328.80K | $-1.42M | $-630.94K |
ABVC BioPharma Dividends
Explore ABVC BioPharma's dividend history, including dividend yield, payout ratio, and historical payments.
ABVC BioPharma News
Read the latest news about ABVC BioPharma, including recent articles, headlines, and updates.
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches.
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1.
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. We are hopeful that this agreement will facilitate the advancement of treatments for Non-Small Cell Lung Cancer (NSCLC) since it covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer. ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1,250,000 in cash after OncoX's next round of fundraising, of which there can be no guarantee; ABVC and its affiliate are also entitled to royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product.
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products.
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine . This recognition is a testament to Dr. Patil's outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary. Within his first year as the Company's CEO, the Company saw a rise in the stock price of its common stock, an increase in its social media presence, and a renewed focus on its essential products.
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024.
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("Know-How") to Senior Paradise, Inc. ("SPI"), who will also lease certain of the Company's properties (the "Land") for further development related to the healthcare industry. The lease, SPI may build a long-term care center for the elderly, plant factories, and good agricultural practices (GAP) for botanical drug products and dietary supplements.
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. ("AiBtl"), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party.
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
FREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc . (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of which 69 enrolled in the study; 60 subjects completed the eight-week study.
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD).
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M.
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company's Quarterly Report on Form 10-Q that was filed earlier today with the Securities and Exchange Commission
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
FREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc . (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment.
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a Taiwanese patent, Application No. 109130285, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
FREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company's ADHD Phase IIb clinical study. These subjects were enrolled at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.
ABVC Executes Cooperation Agreement for Strategic Investments
FREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it had entered into a Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology (Chengdu) Group Co., Ltd. (“中汇联和科技(成都)集团有限公司”) and its affiliated enterprises (“Zhonghui”).
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
FREMONT, CA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that on August 08, 2023, it received a letter from the Nasdaq Listing Qualifications Department notifying the Company that it had regained compliance with the minimum bid price requirement.
ABVC Corporate Update and CEO's Letter to Shareholders
FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
FREMONT, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, neurology, and ophthalmology, announced that the Science Park Administration in Taiwan approved the plan for setting up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus®, a groundbreaking product in retinal detachment surgery, and to pursue the process development work for manufacturing optimization. The plan, proposed by ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation, is to upgrade Vitargus'® manufacturing processes so that ultimately, it can handle the global market supply of Vitargus®. The factory is located in Hsinchu Biomedical Science Park, Taiwan and BioFirst Corporation is targeting to complete the construction in 2024.
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
FREMONT, CA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and ophthalmology, today announced the signing of a legally binding term sheet with a prominent Chinese pharmaceutical company, Xinnovation Therapeutics Co., Ltd that, subject to definitive agreements, is for the exclusive licensing of ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China.
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
FREMONT, CA, July 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has closed on a definitive securities purchase agreement with a single institutional investor, acquiring $1.75 million worth of its common stock in a registered direct offering (the “Offering”).
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
FREMONT, CA, July 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has entered into a definitive securities purchase agreement with a single institutional investor to purchase $1.75 million worth of its common stock in a registered direct offering (the “Offering”).
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it has signed a term sheet to advance a partnership with Zhonghui United Technology (Zhonghui) Group Co., Ltd. and its affiliated enterprises. The partnership contemplates a planned acquisition of real estate assets via an equity transfer, estimated at $7.4 million, all to advance the development of a large-scale health and wellness base in Chengdu, China.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ABVC.